Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Says No To Early Stage Deal-Making, Citing High Likelihood Of Failure

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline's in-licensing efforts will focus on late-stage compounds due to the high risk of earlier stage deals, CEO J.P. Garnier said Feb. 8

You may also be interested in...



India Ready For Chemistry Outsourcing, Wyeth Says; Biology Remains In West

India is currently a viable option for simple chemistry outsourcing and offshoring; however, additional skill development is needed before medicinal chemistry and biology operations can be conducted there, speakers said at the Financial Times Global Pharmaceuticals & Biotechnology conference in London Sept. 18

Garnier’s Vision: GSK To Be “The Most R&D Intensive Company In The World”

GlaxoSmithKline appears ready to turn the typical pharmaceutical company business model on its head, with plans to significantly increase the percentage of sales spent on research & development and reduce spending on selling, general & administrative expenses

Biotech Licensing Often More Cost-Effective Than In-House R&D For Pharma

Large pharmaceutical manufacturers are entering into more early stage licensing deals with biotechs because such deals are often more cost-effective than conducting in-house research, Bayer VP-Business Development Chris Seaton said
UsernamePublicRestriction

Register

SC065972

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel